Business Context and Reporting Period
Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Agios is a commercial-stage biopharmaceutical company focused on rare diseases. Its lead product, PYRUKYND® (mitapivat), is approved for Pyruvate Kinase (PK) deficiency. The company is advancing PYRUKYND for thalassemia and sickle cell disease (SCD), developing tebapivat for myelodysplastic syndromes (MDS) and SCD, and pursuing other pipeline assets including AG-181 and AG-236.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $12,880 | $8,964 | $34,061 | $25,768 |
| Net (Loss) Income | $(103,433) | $947,915 | $(304,742) | $770,248 |
| Operating Expenses | $129,749 | $111,775 | $384,615 | $326,468 |
| Research & Development | $86,796 | $72,455 | $251,479 | $218,476 |
| SG&A | $41,274 | $38,537 | $128,670 | $105,087 |
| Cash & Cash Equivalents | $92,710 | — | — | — |
| Marketable Securities | $1,164,491 | — | — | — |
| Total Liquidity (Cash + Securities) | $1,257,201 | — | — | — |
| Net Cash Used in Operating Activities (9M) | — | — | $(276,764) | $(256,674) |
Note: Q3 2024 net income included a $889.1M gain on sale of contingent payments and a $200M milestone payment from the sale of the oncology business, which were non-recurring.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 44% in Q3 2025 ($12.9M) compared to Q3 2024 ($9.0M), and 32% for the nine months ended Sept 30, 2025 ($34.1M vs $25.8M), driven by increased volume of PYRUKYND.
- Operating Loss: The company returned to a net loss in Q3 2025 ($103.4M) compared to a net income of $947.9M in Q3 2024. The prior year income was heavily influenced by the one-time sale of Vorasidenib royalty rights and milestone payments.
- Expense Increases: R&D expenses rose 20% in Q3 2025 ($86.8M vs $72.5M) due to increased clinical trial costs for tebapivat and PYRUKYND pediatric trials. SG&A increased 7% ($41.3M vs $38.5M) to support commercial preparations for thalassemia.
- Liquidity: Total cash, cash equivalents, and marketable securities stood at approximately $1.3 billion as of September 30, 2025, down from $1.5 billion at year-end 2024, reflecting operating cash burn offset by investment income.
Guidance, Outlook, and Risks
- Regulatory Milestones:
- Thalassemia: The FDA extended the PDUFA date for the PYRUKYND sNDA to December 7, 2025, following a submission of a Risk Evaluation and Mitigation Strategy (REMS) regarding hepatocellular injury. The EMA's CHMP adopted a positive opinion in October 2025, with a final EC decision expected in early 2026. Saudi Arabia approved the indication in August 2025.
- SCD: Topline data for the Phase 3 RISE UP trial is expected in late 2025, with a potential U.S. commercial launch in 2026 if approved.
- Pipeline Updates:
- Tebapivat: Phase 2b enrollment for LR MDS completed in September 2025; topline data expected early 2026. Phase 2 trial in SCD initiated in Q2 2025.
- AG-236: Phase 1 trial initiated in July 2025 for polycythemia vera.
- Liquidity Outlook: Management expects current cash and marketable securities to fund operations for at least the next 12 months. No committed external funding sources exist other than potential Retained Earn-Out Rights from the Vorasidenib sale.
- Risks:
- Regulatory Delays: Potential delays in FDA/EMA approvals for thalassemia and SCD due to safety monitoring requirements (REMS).
- Competition: Significant competition in SCD, thalassemia, and MDS from large pharma and gene therapy companies.
- Supply Chain: Reliance on third-party manufacturers and potential geopolitical impacts on supply chains.
Investor Verification Checklist
- REMS Impact: Verify the final FDA decision on the December 2025 PDUFA date and the specific requirements of the REMS for hepatocellular injury, as this could affect market access.
- Thalassemia Commercialization: Confirm the status of the European Commission's final decision following the positive CHMP opinion and the commercial readiness for the Saudi Arabia launch.
- SCD Trial Data: Monitor the release of topline data for the RISE UP Phase 3 trial in late 2025, which is critical for future revenue projections.
- Cash Burn Rate: Assess the sustainability of the ~$277M operating cash burn over nine months against the $1.3B liquidity position to determine runway without additional financing.
- Alnylam Milestone: Note the $10M milestone payment made to Alnylam in Q3 2025 and track future potential milestone obligations under the license agreement.